Evidence map›Paper›PMID 37089543›Full record

ArticleFrontiers in microbiology2023

Lipopolysaccharide structure modulates cationic biocide susceptibility and crystalline biofilm formation in

O E Clarke, H Pelling, V Bennett, T Matsumoto, G E Gregory, J Nzakizwanayo, A J Slate, A Preston, M Laabei, L J Bock and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Unveiling the hidden arsenal: new insights intoFrontiers in cellular and infection microbiology · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

O E ClarkeDepartment of Life Sciences, University of Bath, Bath, United Kingdom.
H PellingDepartment of Life Sciences, University of Bath, Bath, United Kingdom.
V BennettDepartment of Life Sciences, University of Bath, Bath, United Kingdom.
T MatsumotoDepartment of Biotechnology and Life Sciences, Tokyo University of Agriculture and Technology, Tokyo, Japan.
G E GregoryDepartment of Life Sciences, University of Bath, Bath, United Kingdom.
J NzakizwanayoDepartment of Life Sciences, University of Bath, Bath, United Kingdom.
A J SlateDepartment of Life Sciences, University of Bath, Bath, United Kingdom.
A PrestonDepartment of Life Sciences, University of Bath, Bath, United Kingdom.
M LaabeiDepartment of Life Sciences, University of Bath, Bath, United Kingdom.
L J BockUnited Kingdom Health Security Agency, Salisbury, United Kingdom.
M E WandUnited Kingdom Health Security Agency, Salisbury, United Kingdom.
K IkebukuroDepartment of Biotechnology and Life Sciences, Tokyo University of Agriculture and Technology, Tokyo, Japan.
S GebhardDepartment of Life Sciences, University of Bath, Bath, United Kingdom.
J M SuttonUnited Kingdom Health Security Agency, Salisbury, United Kingdom.
B V JonesDepartment of Life Sciences, University of Bath, Bath, United Kingdom.
University of Bath · GBTokyo University of Agriculture and Technology · JP

Funding

Wellcome Trust
6 · The paper itself

Abstract

Chlorhexidine (CHD) is a cationic biocide used ubiquitously in healthcare settings.

Indexed as

AMRantimicrobialsbiocidebiocide resistancebiofilmcatheter associated urinary tract infectionlipopolysaccharideProteus mirabilis

Identifiers

PMID37089543
PMCPMC10113676
OpenAlexW4362621869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.